Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

<b>Multiple</b> myeloma (MM) represents 1.8% of all new cancer cases in the U.S. While not curable, advances in treatment, including autologous stem cell transplant (ASCT) and maintenance therapy, have dramatically improved progression-free survival (PFS) and overall survival (OS). We pe...

Full description

Bibliographic Details
Main Authors: Jordan Nunnelee, Francesca Cottini, Qiuhong Zhao, Muhammad Salman Faisal, Patrick Elder, Ashley Rosko, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Don M. Benson, Yvonne Efebera, Nidhi Sharma
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
multiple myeloma
novel agents
older
FISH
ASCT
Online Access:https://www.mdpi.com/2072-6694/14/9/2277

Internet

https://www.mdpi.com/2072-6694/14/9/2277

Similar Items